Long Term Results of Venetoclax Combined with FLAG-IDA Induction and Consolidation for Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Intensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax. In the ND cohort, the overall response rate (ORR) was 97%, with a composite complete remission (CRc) rate of 95% and undetectable measurable residual disease (MRD) status by flow cytometry in 90%. The 3-year OS and EFS rates were 66 and 64%, respectively. Outcomes were similar across European LeukemiaNet (ELN) 2022 risk groups. Sixty-four percent transitioned to allogeneic hematopoietic stem cell transplantation (allo-SCT) in CR1. In the RR cohort, the ORR was 67%; CRc rate 41% and flow negative MRD rate 74%; 57% transitioned to allo-SCT. The patients with RR AML in first salvage with wild-type TP53 status had particularly favorable outcomes, with an ORR of 79%, CRc rate of 74% (76% MRD undetectable) and 3-year OS rate of 51%. Infectious and hematologic adverse events were common, with low 30- and 60-day mortality similar to other intensive chemotherapy regimens. FLAG-IDA + VEN is effective for remission induction in both ND and RR AML.ClinicalTrials.gov Identifier: NCT03214562.

References

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

Fernandez H, Sun Z, Yao X, Litzow M, Luger S, Paietta E . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361(13):1249-59. PMC: 4480917. DOI: 10.1056/NEJMoa0904544. View

Kantarjian H, Borthakur G, Daver N, DiNardo C, Issa G, Jabbour E . Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024; 14(1):163. PMC: 11413327. DOI: 10.1038/s41408-024-01143-2. View

Burnett A, Russell N, Hills R, Hunter A, Kjeldsen L, Yin J . Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013; 31(27):3360-8. DOI: 10.1200/JCO.2012.47.4874. View

Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J . Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 2024; 144(7):714-728. DOI: 10.1182/blood.2024024310. View

Roboz G, Sanz G, Griffiths E, Yee K, Kantarjian H, Recher C . Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024; 8(8):2020-2029. PMC: 11103175. DOI: 10.1182/bloodadvances.2023012062. View

Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S . Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740. DOI: 10.1056/NEJMoa1902688. View

Konopleva M, Tari A, Estrov Z, Harris D, Xie Z, Zhao S . Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000; 95(12):3929-38. View

Konopleva M, Letai A . BCL-2 inhibition in AML: an unexpected bonus?. Blood. 2018; 132(10):1007-1012. PMC: 6235069. DOI: 10.1182/blood-2018-03-828269. View

10.

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

11.

Pratz K, Jonas B, Pullarkat V, Thirman M, Garcia J, Dohner H . Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024; 99(4):615-624. DOI: 10.1002/ajh.27246. View

12.

Chua C, Roberts A, Reynolds J, Fong C, Ting S, Salmon J . Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. J Clin Oncol. 2020; 38(30):3506-3517. DOI: 10.1200/JCO.20.00572. View

13.

DiNardo C, Lachowiez C, Takahashi K, Loghavi S, Xiao L, Kadia T . Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021; 39(25):2768-2778. PMC: 8407653. DOI: 10.1200/JCO.20.03736. View

14.

DiNardo C, Lachowiez C, Takahashi K, Loghavi S, Kadia T, Daver N . Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022; 97(8):1035-1043. PMC: 11812953. DOI: 10.1002/ajh.26601. View

15.

Kadia T, Reville P, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y . Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021; 8(8):e552-e561. PMC: 8884174. DOI: 10.1016/S2352-3026(21)00192-7. View

16.

Patel K, Ruiz-Cordero R, Chen W, Routbort M, Floyd K, Rodriguez S . Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn. 2018; 21(1):89-98. PMC: 11773613. DOI: 10.1016/j.jmoldx.2018.08.002. View

17.

Loghavi S, Wei Q, Ravandi F, Quesada A, Routbort M, Hu S . Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol. 2024; 99(10):1959-1968. DOI: 10.1002/ajh.27435. View

18.

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

19.

Wang H, Mao L, Yang M, Qian P, Lu H, Tong H . Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022; 9(6):e415-e424. DOI: 10.1016/S2352-3026(22)00106-5. View

20.

Garciaz S, Hospital M, Alary A, Saillard C, Hicheri Y, Mohty B . Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers (Basel). 2022; 14(8). PMC: 9028084. DOI: 10.3390/cancers14082025. View